To access this element change to forms mode OFF
Grant Award View - GA30212
Optimising the Efficacy of Imetelstat Therapy in Acute Myeloid Leukaemia
GA ID:
GA30212
Agency:
National Health and Medical Research Council (NHMRC)
Approval Date:
25-Oct-2018
Publish Date:
21-Dec-2018
Category:
Medical Research
Grant Term:
1-Jan-2019 to 31-Dec-2021
Value (AUD):
$591,732.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
NHMRC 17/18 1.1 Health and Medical Research
Grant Program:
Project
Grant Activity:
Optimising the Efficacy of Imetelstat Therapy in Acute Myeloid Leukaemia
Purpose:
Acute myeloid leukaemia (AML) is a very aggressive blood cancer that kills about 1,000 Australians every year. AML patients are treated with chemotherapy, however, most patients are not cured by chemotherapy alone and the disease eventually comes back (relapses). We are testing a new type of treatment (imetelstat) for patients with AML that targets the genetic material (DNA) within the leukaemia cells. Our work has shown that this new type of treatment may prevent relapse after chemotherapy.
GO ID:
GO Title:
NHMRC Project Grant Scheme
Internal Reference ID:
GNT1157263
Selection Process:
Targeted or Restricted Competitive
Confidentiality - Contract:
Yes
Confidentiality Reason(s) - Contract:
Privacy Act 1988
Intellectual property
Intellectual property
Confidentiality - Outputs:
Yes
Confidentiality Reason(s) - Outputs:
Intellectual property
Grant Recipient Details
Recipient Name:
QIMR Berghofer Medical Research Institute
Recipient ABN:
31 411 813 344
Grant Recipient Location
Suburb:
Herston
Town/City:
Herston
Postcode:
4006
State/Territory:
QLD
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
QLD
Postcode:
Country:
AUSTRALIA